Enlivex announced that its RAIN token, which represents the bulk of its treasury holdings, has been listed on the HTX cryptocurrency exchange effective April 29, 2026. The listing adds a major global venue to the token’s trading ecosystem.
HTX is a leading global exchange that serves more than 160 countries and recorded a cumulative trading volume of roughly $3.3 trillion in 2025. The move is expected to broaden the token’s secondary market liquidity and reduce the illiquidity risk associated with holding a single volatile asset.
Enlivex’s treasury holdings total approximately 78.8 billion RAIN tokens, valued at about $567 million as of April 27, 2026. The company also holds an exclusive option to acquire up to $918 million of RAIN at $0.003311 per token, a discount that could generate additional shareholder value if exercised.
The RAIN token is the governance and utility token for a decentralized predictions and options protocol built on the Arbitrum network. Enlivex’s dual‑strategy model combines the development of its Allocetra immunotherapy platform with the treasury strategy centered on RAIN, aiming to create value from both clinical and digital‑asset channels.
In 2025, Enlivex reported net income of $1.23 billion, largely driven by unrealized appreciation in its treasury assets, and recorded $2.31 billion in treasury assets as of December 31, 2025. The company’s 2025 treasury strategy included a $212 million private placement to fund the RAIN strategy, not a $2.3 billion investment.
The HTX listing follows a prior Kraken listing that became effective February 9, 2026, and comes as Enlivex prepares to delist from the Tel Aviv Stock Exchange and launch a tokenized share offering on Ondo Global Markets. These steps are part of a broader effort to streamline its capital structure and improve liquidity for both its treasury assets and ordinary shares.
While the RAIN token listing does not alter Enlivex’s clinical pipeline, the company recently received FDA clearance for a Phase 2b trial of its Allocetra therapy for knee osteoarthritis. The dual‑strategy approach positions Enlivex to benefit from potential clinical milestones while leveraging its treasury holdings to support future capital‑raising or partnership opportunities.
Analysts have issued mixed views on Enlivex’s outlook, with a consensus rating of “Hold” and a range of price targets. The company’s focus on both clinical development and treasury strategy reflects a balanced approach to growth, but investors remain cautious about the volatility of its digital‑asset holdings and the uncertain trajectory of its immunotherapy program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.